Akèy › Kansè nan tete › South Carolina › Greenville
Etid klinik pou Kansè nan tete nan Greenville, SC
12 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Greenville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Ap rekriteFaz 3
- Bon Secours St Francis Cancer Center, Greenville
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Prisma Health Cancer Institute - Faris, Greenville
- Prisma Health Greenville Memorial Hospital, Greenville
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Ap rekriteFaz 3
- St Francis Cancer Center ( Site 0093), Greenville
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Ap rekriteFaz 3
- Bon Secours - St. Francis Hospital, Greenville
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- Saint Francis Hospital, Greenville
- Prisma Health Cancer Institute - Butternut, Greenville
- Prisma Health Cancer Institute - Faris, Greenville
- ak 2 plis
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Ap rekriteFaz 2/3
- St Francis Cancer Center, Greenville
E-Mindfulness Approaches for Living After Breast Cancer
Ap rekriteFaz 3
- Prisma Health Cancer Institute - Butternut, Greenville
- Prisma Health Cancer Institute - Faris, Greenville
- Prisma Health Cancer Institute - Eastside, Greenville
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Ap rekriteFaz 1/2
- Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053), Greenville
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Saint Francis Hospital, Greenville
- Prisma Health Cancer Institute - Butternut, Greenville
- Prisma Health Cancer Institute - Faris, Greenville
- ak 2 plis
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Greenville
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Ap rekriteFaz 3
- Prisma Health Cancer Institute - Butternut, Greenville
- Prisma Health Cancer Institute - Faris, Greenville
- Prisma Health Cancer Institute - Eastside, Greenville
Near Infrared Spectroscopy (NIRS) as a Method for Measuring Oxidative Capacity of Skeletal Muscle Mitochondria in Breast Cancer and All Gynecological Cancer Patients
Ap rekriteEtid obsèvasyon
- Prisma Health Cancer Institute, Greenville
Etid Kansè nan tete nan lòt vil
- New York City, NY136 etid
- Houston, TX126 etid
- Boston, MA112 etid
- Nashville, TN81 etid
- Los Angeles, CA73 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Queens, NY64 etid
- Durham, NC64 etid
- Chicago, IL59 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Greenville
- Kansè Poumon ki pa ti selil15 etid
- Leksemi mieloïd egi10 etid
- Kansè (tout kalite)9 etid
- Obèsite9 etid
- Kansè poumon9 etid
- Sipwa8 etid
- Kansè pwostat7 etid
- Kansè kolorektal7 etid
- Kansè lestomak6 etid
- Maladi atè perifèrik5 etid
- Limfòm Burkitt5 etid
- Melanom5 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.